The therapeutic implications of oestrogens in cardiovascular diseases

Bibliography

• GODFRAIND T: Calcium antagonists and vasodilation. Pharmacol. Ther. (1994) 64:37–75.
   PubMed Web of Science ®Google Scholar
• •A thorough review of calcium antagonists.
   Google Scholar
• CATAPANO AL: Calcium antagonists and atherosclerosis. Eur. Heart J. (1997) 97(Suppl. A) :A80–A86.
   Google Scholar
• ••A good review of in vitro and in vivo experimental evidence of CEBs in atherosclerosis.
   Google Scholar
• EPSTEIN M: Calcium antagonists: still appropriate as first-line antihypertensive agents. Am. J. Hypertens. (1996) 9:110–121.
   PubMed Web of Science ®Google Scholar
• GODFRAIND T: Calcium channels in smooth muscle. Ann. NY Acad. Sci. (1988) 522:312–327.
   PubMed Web of Science ®Google Scholar
• QUARTAROLI M, GAMBINI F, TARTER G, et al.: The haemodynamic effects of lacidipine in anesthetized dogs: comparison with nitrendipine, amlodipine, verapamil and diltiazem. J. Cardiovasc. Pharmacol. (1991) 18:326–336.
   PubMed Web of Science ®Google Scholar
• ROSS R: The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature (1993) 362:801–809.
   PubMed Web of Science ®Google Scholar
• Minisci F (Ed.), Kluwer Academic Publishers, Netherlands (1997) :193–221.
   Google Scholar
• ZANCHETI A: Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. Clin. Exp. Hypertens. (1996) 18:489–499.
   PubMed Web of Science ®Google Scholar
• DE FEYTER PJ, VOS J, DECKERS JW: Progression and regression of the atherosclerotic plaque. Eur. Heart J. (1995) 16 (Suppl. I) :26–30.
   Web of Science ®Google Scholar
• HANSSON L: How to study the role of hypertension in atherosclerosis. Lessons from MIDAS, Multicentre Isradipine Diuretic Atherosclerosis Study. Blood Pressure (1996) 4(Suppl.):16–19.
   PubMed Web of Science ®Google Scholar
• BERNINI F, SOMA MR, CORSINI A, PAOLETTI R: Experimental and clinical effects of isradipine relevant to atherosclerosis. Am. J. Hypertens. (1994) 7:30S–34S.
   Google Scholar
• FURBERG CD, ADAMS HP, Jr., APPLEGATE WB, et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation (1994) 90:1679–1687.
   PubMed Web of Science ®Google Scholar
• JOST S, DECKERS JW, NIKUTTA P, et al.: Evolution of coronary stenoses is related to baseline severity - a prospective quantitative angiographic analysis in patients with moderate coronary disease. INTACT Investigators. International Nifedipine Trial on Antiatherosclerotic Therapy. Eur. Heart J. (1994) 15:648–653.
   PubMed Web of Science ®Google Scholar
• APPLEGATE WB, FURBERG CD, BYINGTON RP, et al.: The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA (1997) 277:297–298.
   PubMed Web of Science ®Google Scholar
• BOND G, DAL PALU C, HANSSON L, et al.: European Lacidipine Study on Atherosclerosis. J. Hypertens. (1993) 11 (Suppl. 5) :S405–S407.
   Google Scholar
• MAGNANI B, DAL PALU C, ZANCHETTI A: Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators. Drugs (1992) 44 (Suppl. 1) :128–133.
   PubMedGoogle Scholar
• JUKEMA JVV, ZWINDERMAN AH, VAN BOVEN AL, et al.: Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler. Thromb. Vasc. Biol. (1996) 16:425–430.
   PubMed Web of Science ®Google Scholar
• •First evidence that there might be synergy between CEBs and HMG-CoA reductase inhibitors.
   Google Scholar
• IMS®: MIDAS Database (1996).
   Google Scholar
• TOPPER JN, CAI J, FALB D, GIMBRONE A, Jr.: Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA (1996) 93:10417–10422.
   PubMed Web of Science ®Google Scholar
• NAYLER WG: New therapeutic trends in calcium antagonism. Are they meaningful Am. J. Hypertens. (1994) 7:126S–130S.
   Google Scholar
• GIACOMETTI A, MICHELI D, GAVIRAGHI G, et al.: Quantification of the calcium antagonism of lacidipine by kinetic analysis. J. Pharmacol. Exp. Ther. (1994) 269:424–429.
   PubMed Web of Science ®Google Scholar
• ZITO M, ABATE G, CERVONE C, et al.: Effects of antihypertensive therapy with lacidipine on ambulatory blood pressure in the elderly. J. Hypertens. (1991) 9 (Suppl. 3) :S79–583.
   Google Scholar
• ZANCHETTI A: Lacidipine. The Monograph. Adis International, Milan (1997).
   Google Scholar
• Bellomo G, Finardi G, Maggi E, Rice-Evans (Eds.), Richelieu Press, London (1995):431–456.
   Google Scholar
• •Review of CEBs and antioxidant activity.
   Google Scholar
• Weatherall DJ, Ledingham JGG, Warrel DA (Eds.), Oxford University Press, Oxford (1996) :2305–2318.
   Google Scholar
• WENGER NK: Coronary heart disease: an older woman's major health risk. Br. Med. J. (1997) 315:1085–1090.
   PubMed Web of Science ®Google Scholar
• MANIADAKIS N: Coronary heart disease statistics: economic cost supplement. British Heart Foundation, London (In press).
   Google Scholar
• Julian DG, Wenger NK (Eds.), Martin Dunitz, London (1997):7–20.
   Google Scholar
• •A very readable epidemiological review.
   Google Scholar
• GORDON T, KANNEL WB, HJORTLAND MC, MCNAMARA PM: Menopause and coronary heart disease: the Framingham study. Ann. Intern. Med. (1978) 89:157–161.
   PubMed Web of Science ®Google Scholar
• HUNT K, VESSEY M, MCPHERSON K: Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br. J. Obstet. Gynaecol. (1990) 97:1080–1086.
   PubMedGoogle Scholar
• GRADY D, RUBIN SN, PETITTI DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. (1992) 117:1016–1037.
   PubMed Web of Science ®Google Scholar
• ••Paper commissioned by the American College of Physicians. A clear account of the risks andbenefits of HRT.
   Google Scholar
• GRODSTEIN F, STAMPFER MJ, COLDITZ GA, et al.: Postmenopausal hormone therapy and mortality. New Engl. J. Med. (1997) 336:1769–1775.
   PubMed Web of Science ®Google Scholar
• ••The largest long-term cohort study on HRT and mortality.
   Google Scholar
• ROSS R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 362:801–809.
   PubMed Web of Science ®Google Scholar
• Isselbacher KJ, Braunwald E (Eds.), McGraw-Hill, New York (1994):1106–1111.
   Google Scholar
• Weatherall DJ, Ledingham JGG, Warrel DA (Eds.), Oxford University Press, Oxford (1996):2289–2295.
   Google Scholar
• BRAUNWALD E: Shattuck Lecture - Cardiovascular medicine at the turn of the Millennium: triumphs, concerns, and opportunities. New Engl. J. Med. (1997) 337:1360–1369.
   PubMed Web of Science ®Google Scholar
• MCKINLEY SM, BRAMBILLA DJ, POSNER JG: The normal menopause transition. Am. J. Hum. Biol. (1992) 4:37–46.
   PubMed Web of Science ®Google Scholar
• HILL K: The demography of menopause. Maturitas (1996) 23:113–127.
   PubMed Web of Science ®Google Scholar
• HAMMOND CB: Women's concern with hormone replacement therapy - compliance issues. Fertit Steril. (1994) 62 (Suppl. 2):157S–160S.
   Google Scholar
• WILKES HC, MEADE TW: Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. Br. Med. J. (1991) 302:1317–1320.
   PubMed Web of Science ®Google Scholar
• EIKEN P, KOLTHOFF N: Compliance with long-term oral hormonal replacement therapy. Maturitas (1995) 22:97–103.
   PubMed Web of Science ®Google Scholar
• BELCHETZ PE: Hormonal treatment of postmenopausal women. New Engl. J. Med. (1994) 330:1062–1071.
   PubMed Web of Science ®Google Scholar
• •A review of HRT treatment for everyday practice.
   Google Scholar
• PAGANINI-HILL A, ROSS RK, HENDERSON BE: Postmenopausal oestrogen treatment and stroke: a prospective study. Br. Med. J. (1988) 297:519–522.
   PubMed Web of Science ®Google Scholar
• PAGANINI-HILL A: Estrogen replacement therapy and stroke. Prog. Cardiovasc. Dis. (1995) 38:223–242.
   PubMed Web of Science ®Google Scholar
• PAGANINI-HILL A, HENDERSON VW: Estrogen deficiency and the risk of Alzheimer's disease in women. Am. J. Epidemiol. (1994) 140:256–261.
   PubMed Web of Science ®Google Scholar
• TANG M-X, JACOBS D, STERU Y et al.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 348:429–432.
   PubMed Web of Science ®Google Scholar
• FERNANDES E, LA VECCHIA C, D'AVANZO B, et al.: Oral contraceptives, hormone replacement therapy and the risk of colorectal cancer. Br. J. Cancer (1996) 73:1431–1435.
   PubMed Web of Science ®Google Scholar
• COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER: Breast cancer and hormonal replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet (1997) 350:1047–1059.
   PubMed Web of Science ®Google Scholar
• ••A recent paper examining the link between HRT and breast cancer.
   Google Scholar
• GUTTHANN SP, RODRIGUEZ LAG, CASJEUSAGUE J, et al.: Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br. Med. J. (1997) 314:776–800.
   Web of Science ®Google Scholar
• Carr BR, Blackwell RE (Eds.), Appleton & Lange, Norwalk (1993):199–200.
   Google Scholar
• KUHL H: Pharmacokinetics of oestrogens and progestins. Maturitas (1990) 12:171–197.
   PubMed Web of Science ®Google Scholar
• Speroff L, Glass RH, Kase NG (Eds.), Williams and Wilkins, Baltimore (1978):19.
   Google Scholar
• Messerli FH (Ed.), Marcel Dekker, New York (1996):6.
   Google Scholar
• GUYTON AC: Female physiology before pregnancy and the female hormones. In: Human Physiology and the Mechanism of Disease. WB Saunders Co., Philadelphia (1992):616–618.
   Google Scholar
• LIN AL, GONZALEZ R, CAREY K, SHAIN SA: Estradiol 17-beta affects estrogen receptor distribution and elevates progesterone receptor content in baboon aorta. Atherosclerosis (1986) 6:495–504.
   Google Scholar
• LORDOSO DW, KEARNEY M, KIM EA, JEKANOWSKI J, ISNER JM: Variable expression of estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation (1994) 89:1501–1510.
   PubMed Web of Science ®Google Scholar
• COLLINS P: Vascular aspects of oestrogen. Maturitas (1996) 23:217-226.A readable summary of the effect of oestrogen on blood vessels.
   PubMed Web of Science ®Google Scholar
• PROUDLER AJ, AHMED HAI, CROOK D, et al.: Hormone replacement therapy and serum angiotensin converting enzyme activity in postmenopausal women. Lancet (1995) 346:89–90.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN ME, KARAS RH: Oestrogen and the blood vessel wall. Curr. Opin. Cardiol. (1994) 9:619–626.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the subject.
   Google Scholar
• GANGAR KF, VYAS S, WHITEHEAD M, et al.: Pulsatility index in the internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet (1991) 338:834–842.
   Google Scholar
• COLLINS P, ROSANO GMC, SARREL PM, et al.: 170 -estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation (1995) 92:24–30.
   PubMed Web of Science ®Google Scholar
• BONITHON-COPP C, SCARABIN PY, DARNE B, et al.: Menopause related changes in lipoproteins and some other cardiovascular risk factors. Int. J. Epidemiol. (1990) 19:42–48.
   PubMed Web of Science ®Google Scholar
• JENSEN J, NILAS L, CHRISTIANSEN C: Influence of menopause on serum lipids and lipoproteins. Maturitas (1990) 12:321–331.
   PubMed Web of Science ®Google Scholar
• STEVENSON J, CROOK D, GODSLAND I: Effects of age and menopause on lipid metabolism of healthy women. Atherosclerosis (1993) 98:83–90.
   PubMed Web of Science ®Google Scholar
• ••A large cross-sectional study of menopausal changes in lipids and lipoproteins independentof age.
   Google Scholar
• ASSMANN G, CULLEN P, SCHULTE H: HRT, plasma risk factors and cardiovascular disease. Eur. Menopause J. (1996) 3:203–208.
   Google Scholar
• KESSLER CM, SZYMANSKI MM, SHAMSIP OUR Z, et al.: Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet. Gynecol. (1997) 89:326–331.
   PubMed Web of Science ®Google Scholar
• SPEROFF L, ROUAN J, SYMONS J, et al.: The comparative effect on bone density, endometrium and lipids of continuous hormones as replacement therapy (CHART) study. J. Am. Med. Assoc. (1996) 276:1397–1403.
   PubMed Web of Science ®Google Scholar
• Asch RH, Studd JVVW (Eds.), Parthenon, Carnforth (1993):261–271.
   Google Scholar
• CHEANG E, SITRUK-WARE R, SAMSIOE G: Transdermal oestradiol and cardiovascular risk factors. Br. J. Obstet. Gynaecol. (1994) 101:571–581.
   PubMedGoogle Scholar
• THE WRITING GROUP FOR THE PEPI TRIAL: Effects of estrogens and estrogen-progestin regiments on heart disease risk factors in postmenopausal women. JAMA (1995) 273:199–208.
   PubMed Web of Science ®Google Scholar
• CROOK D, GODSLAND IF, HULL J, STEVENSON JC: Hormone replacement therapy with dydrogesterone and beta oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br. J. Obstet. Gynaecol. (1997) 104:298–304.
   PubMedGoogle Scholar
• LEY CJ, LEES B, STEVENSON JC: Sex and menopause associated changes in body fat distribution. Am. J. Clin. Nutr. (1992) 55:950–954.
   PubMed Web of Science ®Google Scholar
• LAPIDUS L, BENGTSSON C, LARSSON B, et al.: Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of Gothenburg, Sweden. Br. Med. J. (1984) 289:1257–1261.
   PubMed Web of Science ®Google Scholar
• HAARBO J, MARSLEW U, GODFREDSEN A, CHRISTIANSEN C: Postmenopausal hormonal replacement therapy prevents central distribution of body fat after menopause. Metabolism (1991) 40:1323–1326.
   PubMed Web of Science ®Google Scholar
• GASPARD UJ, GOTTAL J-M, DEN BRULE FA: Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas (1995) 21:171–178.
   PubMed Web of Science ®Google Scholar
• STEVENSON JC: Mechanisms whereby oestrogens influence arterial health. Eur. J. Obstet. Gynaecol. (1996) 65:39–42.
   PubMed Web of Science ®Google Scholar
• MEADE TW, NORTH WRS, CHAKRABARTI R, et al.: Haemostatic function and cardiovascular death: early results of a prospective study. Lancet (1980) i:1050–1054.
   Google Scholar
• MEADE TW, HAINES AP, IMESON JD, STERLING Y, THOMPSON SG: Menopausal status and haemostatic variables. Lancet (1983) i:22–24.
   Google Scholar
• MEADE TW, RUDDOCK V, STERLING Y, CHAKRABARTI R, MILLER JG: Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet (1993) 342:1076–1079.
   PubMed Web of Science ®Google Scholar
• GILBERT J, ESTELLES A, CANO A, et al.: The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal women. Am. J. Obstet. Gynecol. (1995) 793:1849–1854.
   Web of Science ®Google Scholar
• KOH KK, MINCEMOYER R, BUI MN, et al.: Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. New Engl. J. Med. (1997) 336:683–690.
   PubMed Web of Science ®Google Scholar
• BAR J, TEPPER R, FUCHS J, et al.: The effect of estrogen replacement therapy on platelet aggregation adenosine triphosphate release of postmenopausal women. Obstet. Gynecol. (1993) 81:261–264.
   PubMed Web of Science ®Google Scholar
• BJARNASON NH, BJARNASON K, HAARBO J, et al.: Tibolone: influence of markers of cardiovascular disease. J. Clin. Endocrinol. Metab. (1997) 82:1752–1756.
   PubMed Web of Science ®Google Scholar
• RYMER J, CROOK D, SIDHU M, CHAPMAN M, STEVENSON JC: Effects of tibolone on serum concentration of lipoprotein(a) in postmenopausal women. Acta Endocrinologica (1993) 128:259–262.
   PubMedGoogle Scholar
• Data on file. Wyeth-Ayerst Research.
   Google Scholar
• PURDIE DW: Selective oestrogen receptor modulation: HRT replacement therapy Br. J. Obstet. Gynaecol. (1997) 104:1103–1105.
   Google Scholar
• DELMAS PD, BJARNASON NH, MITLAK BH, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentration and uterine endometrium in postmenopausal women. New Engl./ Med. (1997) 337:1641–1647.
   Google Scholar
• DVVYER JT, COLDIN BR, SAUL N, et al.: Tofu and soy drinks contain phytoestrogens. J. Am. Diet Assoc. (1994) 94:739–743.
   PubMed Web of Science ®Google Scholar
• MIKSICEK RJ: Commonly occurring plant flavonoids have estrogenic activity. Mol. Pharmacol. (1993) 44:37–43.
   PubMed Web of Science ®Google Scholar
• MURKIES AL, LOMBARD C, STRAUSS BJG, et al.: Dietary flour supplementation decreases postmenopausal hot flushes: effect of soy and wheat. Maturitas (1995) 21:189–195.
   PubMed Web of Science ®Google Scholar